HRP20210981T1 - Imidazolonil kinolini i njihova uporaba kao inhibitori atm kinaze - Google Patents
Imidazolonil kinolini i njihova uporaba kao inhibitori atm kinaze Download PDFInfo
- Publication number
- HRP20210981T1 HRP20210981T1 HRP20210981TT HRP20210981T HRP20210981T1 HR P20210981 T1 HRP20210981 T1 HR P20210981T1 HR P20210981T T HRP20210981T T HR P20210981TT HR P20210981 T HRP20210981 T HR P20210981T HR P20210981 T1 HRP20210981 T1 HR P20210981T1
- Authority
- HR
- Croatia
- Prior art keywords
- pyrazol
- methyl
- tautomer
- stereoisomer
- solvate
- Prior art date
Links
- BAHVJMJZUDCTPT-UHFFFAOYSA-N 4-quinolin-2-ylimidazol-2-one Chemical class O=C1N=CC(C=2N=C3C=CC=CC3=CC=2)=N1 BAHVJMJZUDCTPT-UHFFFAOYSA-N 0.000 title 1
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- -1 methoxy, ethoxy, propoxy, piperazinyl Chemical group 0.000 claims 38
- 150000001875 compounds Chemical class 0.000 claims 14
- 150000003839 salts Chemical class 0.000 claims 14
- 239000012453 solvate Substances 0.000 claims 14
- 125000004432 carbon atom Chemical group C* 0.000 claims 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 239000002246 antineoplastic agent Substances 0.000 claims 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 3
- 125000003226 pyrazolyl group Chemical group 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 125000000623 heterocyclic group Chemical class 0.000 claims 2
- 125000002883 imidazolyl group Chemical group 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 125000001425 triazolyl group Chemical group 0.000 claims 2
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 206010070834 Sensitisation Diseases 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000005336 allyloxy group Chemical group 0.000 claims 1
- 125000002393 azetidinyl group Chemical group 0.000 claims 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 230000005865 ionizing radiation Effects 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 230000008313 sensitization Effects 0.000 claims 1
- 125000004434 sulfur atom Chemical group 0.000 claims 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 1
- 125000000437 thiazol-2-yl group Chemical group [H]C1=C([H])N=C(*)S1 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Claims (14)
1. Spoj s formulom (I)
[image]
naznačen time što
R1 je metil,
R3 označava nerazgranat ili razgranat alkil koji ima 1, 2 ili 3 C atoma, gdje, neovisno jedan od drugoga, 1, 2, 3, 4 ili 5 H atoma mogu biti zamijenjeni s Hal,
Het1 je odabran iz niza koji čine pirazolil, triazolil i imidazolil, pri čemu Het1 može biti nesupstituiran ili mono- ili disupstituiran, neovisno jedan od drugoga, s alkilom, koji može biti nesupstituiran ili mono- ili polisupstituiran s Hal, -OY, -NYY, Hal i -Het2,
HET označava 5-eročlani monociklički aromatski heterocikl, gdje je ovaj heterocikl povezan s N atomom kostura preko prstenskog C atoma i gdje je ovaj heterocikl odabran od pirazolila, tiazolila i imidazolila i može biti nesupstituiran ili supstituiran s jednim, dva ili tri supstituenta, koji su odabrani, neovisno jedan od drugoga, iz skupine koja sadrži: Hal, A, Het2, -(CY2)p-OY, -(CY2)p-OZ, -(CY2)p-O-Het2, -(CY2)p-O-(CY2)t-Het2, -(CY2)p-O-(CY2)t-NYY, -(CY2)p-O-(CY2)t-OY, -(CY2)p-NYY, -(CY2)p-COOY, -(CY2)p-CO-NYY, -(CY2)p-NY-COY,
A svaki puta neovisno označava nerazgranat ili razgranat alkil koji ima 1, 2, 3, 4, 5, 6, 7, 8, 9 ili 10 C atoma, gdje, neovisno jedan od drugoga, 1, 2, 3, 4, 5, 6 ili 7 H atoma mogu biti zamijenjeni s Hal,
Het2 označava monociklički zasićeni heterocikl koji ima 2, 3, 4, 5, 6 ili 7 C atoma i 1, 2, 3 ili 4 N, O i/ili S atoma, koji mogu biti nesupstituirani ili monosupstituirani s A,
Y označava H ili A,
Z označava nerazgranat ili razgranat alkenil koji ima 2, 3, 4, 5, 6, 7, 8, 9 ili 10 C atoma, gdje, neovisno jedan od drugoga, 1, 2, 3, 4, 5, 6 ili 7 H atoma mogu biti zamijenjeni s Hal,
Hal označava F, Cl, Br ili I, i
p označava 0, 1, 2, 3, 4, 5 ili 6
t označava 1, 2, 3, 4, 5 ili 6,
i/ili njegova farmaceutski upotrebljiva sol, solvat, tautomer ili stereoizomer.
2. Spoj s formulom (I) prema patentnom zahtjevu 1, naznačen time što HET može biti supstituiran s jednim, dva ili tri supstituenta koji su odabrani, neovisno jedan od drugoga, iz skupine koja sadrži: F, Cl, metil, etil, propil, izopropil, metoksi, etoksi, propoksi, piperazinil, tetrahidropiranil, 2-metoksietoksi, 2-hidroksietoksi, fluorometoksi, difluorometoksi, N-metilkarbamoil (-C(=O)-NH-CH3), 2-metilaminoetoksi, 1-metil-azetidin-3-ilmetoksi, trideuteriometoksi, trifluorometoksi, aliloksi i azetidiniloksi, i/ili njegova farmaceutski upotrebljiva sol, solvat, tautomer ili stereoizomer.
3. Spoj s formulom (I) prema patentnom zahtjevu 1 ili 2, naznačen time što je HET odabran iz skupa koji čine: 1H-pirazol-4-il, 1-etil-3-metil-1H-pirazol-4-il, 1,2-dimetil-1H-pirazol-4-il, 1,3-dimetil-1H-pirazol-4-il, 1-metil-1 H-pirazol-4-il, 1-(tetrahidropiran-4-il)-1H-pirazol-4-il, 2-metil-2H-pirazol-3-il, 3-metil-1H-pirazol-4-il, 2-metilol-4-il, 3,5-dimetil-1H-pirazol-4-il, 3-fluoro-1-metilpirazol-4-il, tiazol-2-il, i 1-metil-1H-imidazolil, i/ili njegova farmaceutski upotrebljiva sol, solvat, tautomer ili stereoizomer.
4. Spoj s formulom (I) prema patentnom zahtjevu 1, 2 ili 3, naznačen time što Het1 je pirazolil, koji može biti nesupstituiran ili supstituiran kako je definirano u patentnom zahtjevu 1, i/ili njegova farmaceutski upotrebljiva sol, solvat, tautomer ili stereoizomer.
5. Spoj s formulom (I) prema patentnom zahtjevu 1, 2 ili 3, naznačen time što Het1 je triazolil, poželjno 1,2,3-triazolil, koji može biti nesupstituiran ili supstituiran kako je definirano u patentnom zahtjevu 1, i/ili njegova farmaceutski upotrebljiva sol, solvat, tautomer ili stereoizomer.
6. Spoj s formulom (I) prema jednom od patentnih zahtjeva 1 do 4, naznačen time što Het1 je nesupstituiran ili supstituiran s jednim ili dva supstituenta odabrana, neovisno jedan od drugoga, od metila, etila, amino, metoksi, fluorometila, difluorometila, fluora, azetidinila, i/ili njegova farmaceutski upotrebljiva sol, solvat, tautomer ili stereoizomer.
7. Spoj s formulom (I) prema bilo kojem od patentnih zahtjeva 1 do 4, naznačen time što je Het1 naznačen time što je odabran iz skupa koji čine: 1H-pirazol-4-il, 2H-pirazol-3-il, 1H-pirazol-3-il, 1-metil-1H-pirazol-4-il, 3-metil-1H-pirazol-4-il, 5-metil-1H-pirazol-3-il, 4-metil-1H-pirazol-3-il, 1-fluorometil-1H-pirazol-4-il, 1-difluorometil-1H-pirazol-4-il, 1,3-dimetil-1H-pirazol-4-il, 1-etil-1H-pirazol-4-il, 1-etil-3-metil-1H-pirazolil, 3-fluoro-1-metil-1H-pirazol-4-il, 3-amino-1H-pirazol-5-il, 2H-1,2,3-triazol-4-il, 3H-1,2,3-triazol-4-il-, 1-metil-1H-1,2,3-triazol-4-il, 2-metil-2H-1,2,3-triazol-4-il, 2-amino-1H-imidazol-4-il, i 1-(azetidin-3-il)-3-metil-1H-pirazol-4-il, i/ili njegova farmaceutski upotrebljiva sol, solvat, tautomer ili stereoizomer.
8. Spoj s formulom (I) prema bilo kojem od patentnih zahtjeva 1 do 7, naznačen time što R3 označava metil, i/ili njegova farmaceutski upotrebljiva sol, solvat, tautomer ili stereoizomer.
9. Spoj prema patentnom zahtjevu 1, naznačen time što je odabran iz skupa koji čine:
[image]
[image]
[image]
[image]
i/ili njihova farmaceutski upotrebljiva sol, solvat, tautomer ili stereoizomer.
10. Spoj prema bilo kojem od patentnih zahtjeva 1 do 9 i/ili njegova farmaceutski upotrebljiva sol, solvat, tautomer ili stereoizomer, naznačen time što je za uporabu kao lijek.
11. Spoj prema bilo kojem od patentnih zahtjeva 1 do 9 i/ili njegova farmaceutski upotrebljiva sol, solvat, tautomer ili stereoizomer, naznačen time što je za uporabu u liječenju raka, tumora i/ili metastaza, po izboru u kombinaciji s radioterapijom ili najmanje jednim sredstvom protiv raka.
12. Spoj prema jednom od patentnih zahtjeva 1 do 9 i/ili njegova farmaceutski upotrebljiva sol, solvat, tautomer ili stereoizomer, naznačen time što je za uporabu u senzibilizaciji stanica karcinoma na sredstvo protiv raka i/ili ionizirajuće zračenje.
13. Farmaceutski pripravak naznačen time što sadrži učinkovitu količinu najmanje jednog spoja prema jednom od patentnih zahtjeva 1 do 9 i/ili njegovu farmaceutski upotrebljivu sol, solvat, tautomer ili stereoizomer, po izboru zajedno s najmanje jednim farmaceutski podnošljivim pomoćnim sastojkom.
14. Komplet koji se sastoji od zasebnih pakiranja
(a) učinkovite količine spoja prema jednom od patentnih zahtjeva 1 do 9 i/ili njegove farmaceutski upotrebljive soli, solvata, tautomera ili stereoizomera, i
(b) učinkovite količine sredstva protiv raka.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15000968 | 2015-04-02 | ||
| EP19172903.7A EP3560924B1 (de) | 2015-04-02 | 2016-03-31 | Imidazolonylchinoline und deren verwendung als atm-kinase-inhibitoren |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20210981T1 true HRP20210981T1 (hr) | 2021-09-17 |
Family
ID=52814780
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20191396 HRP20191396T1 (hr) | 2015-04-02 | 2019-08-01 | Imidazolonilkinolini i njihova uporaba kao inhibotora atm kinaze |
| HRP20210981TT HRP20210981T1 (hr) | 2015-04-02 | 2021-06-23 | Imidazolonil kinolini i njihova uporaba kao inhibitori atm kinaze |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20191396 HRP20191396T1 (hr) | 2015-04-02 | 2019-08-01 | Imidazolonilkinolini i njihova uporaba kao inhibotora atm kinaze |
Country Status (24)
| Country | Link |
|---|---|
| US (5) | US10457677B2 (hr) |
| EP (3) | EP3277681B1 (hr) |
| JP (2) | JP6791873B2 (hr) |
| KR (2) | KR102652052B1 (hr) |
| CN (3) | CN107889488B (hr) |
| AU (3) | AU2016239270B2 (hr) |
| BR (1) | BR122019005502B1 (hr) |
| CA (1) | CA2981365A1 (hr) |
| DK (2) | DK3560924T3 (hr) |
| ES (3) | ES2880626T3 (hr) |
| HR (2) | HRP20191396T1 (hr) |
| HU (2) | HUE045477T2 (hr) |
| IL (3) | IL254714B (hr) |
| LT (2) | LT3560924T (hr) |
| MX (2) | MX2020011558A (hr) |
| PL (2) | PL3277681T3 (hr) |
| PT (2) | PT3560924T (hr) |
| RS (2) | RS59139B1 (hr) |
| RU (1) | RU2743343C2 (hr) |
| SG (2) | SG10202002181UA (hr) |
| SI (2) | SI3277681T1 (hr) |
| TR (1) | TR201911244T4 (hr) |
| WO (1) | WO2016155884A1 (hr) |
| ZA (1) | ZA201707423B (hr) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2880626T3 (es) * | 2015-04-02 | 2021-11-25 | Merck Patent Gmbh | Imidazolonilquinolinas |
| GB201516504D0 (en) * | 2015-09-17 | 2015-11-04 | Astrazeneca Ab | Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer |
| GB201519406D0 (en) * | 2015-11-03 | 2015-12-16 | Astrazeneca Ab | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer |
| WO2018153365A1 (zh) * | 2017-02-27 | 2018-08-30 | 上海瑛派药业有限公司 | 取代的稠合杂芳三环化合物作为激酶抑制剂及其应用 |
| JOP20190209A1 (ar) * | 2017-03-16 | 2019-09-12 | Astrazeneca Ab | مركبات إيميدازو [ 4، 5-c ] كينولين-2-أون ديوترومية واستخدامها في علاج السرطان |
| AU2019206623A1 (en) | 2018-01-12 | 2020-07-16 | Prolynx Llc | Synergistic cancer treatment |
| US20210353614A1 (en) * | 2018-03-14 | 2021-11-18 | Merck Patent Gmbh | Compounds and uses thereof to treat tumors in a subject |
| CN111989323A (zh) | 2018-04-12 | 2020-11-24 | 拜耳公司 | 作为农药的n-(环丙基甲基)-5-(甲基磺酰基)-n-{1-[1-(嘧啶-2-基)-1h-1，2，4-***-5-基]乙基}苯甲酰胺衍生物及相应的吡啶甲酰胺衍生物 |
| WO2019201283A1 (en) * | 2018-04-20 | 2019-10-24 | Xrad Therapeutics, Inc. | Dual atm and dna-pk inhibitors for use in anti-tumor therapy |
| CN110386932A (zh) * | 2018-04-20 | 2019-10-29 | 艾科思莱德制药公司 | 用于抗肿瘤疗法中的双重atm和dna-pk抑制剂 |
| GB201814487D0 (en) * | 2018-09-06 | 2018-10-24 | Cycle Pharmaceuticals Ltd | Cancer |
| CN109045042A (zh) * | 2018-09-21 | 2018-12-21 | 上海交通大学医学院附属上海儿童医学中心 | Atm抑制剂在制备抑制急性淋巴细胞性白血病复发的药物中的应用 |
| BR112021005989A2 (pt) * | 2018-09-30 | 2021-06-29 | Medshine Discovery Inc. | derivados de quinolino-pirrolidin-2-ona e aplicação dos mesmos |
| EP3947375B1 (en) | 2019-03-27 | 2024-04-03 | Merck Patent GmbH | Imidazolonylquinoline compounds and therapeutic uses thereof |
| CN114258301A (zh) * | 2019-07-30 | 2022-03-29 | 艾科思莱德制药公司 | 用于抗肿瘤疗法中的双重atm和dna-pk抑制剂 |
| IL292613A (en) | 2019-11-01 | 2022-07-01 | Ares Trading Sa | Combined inhibition of pd-1, tgf-beta and atm along with radiotherapy for cancer treatment |
| EP4069366A1 (en) | 2019-12-04 | 2022-10-12 | CHDI Foundation, Inc. | Atm kinase inhibitors and compositions and methods of use thereof |
| CN115003672A (zh) * | 2020-01-09 | 2022-09-02 | 南京明德新药研发有限公司 | 喹啉并咪唑类化合物及其应用 |
| CN115380031A (zh) * | 2020-03-30 | 2022-11-22 | 南京明德新药研发有限公司 | 作为atm抑制剂的喹啉并吡咯烷-2-酮类化合物的晶型及其应用 |
| JP2023530004A (ja) * | 2020-06-18 | 2023-07-12 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | ウイルス感染症の処置のための化合物 |
| TW202216209A (zh) | 2020-06-24 | 2022-05-01 | 英商阿斯特捷利康英國股份有限公司 | 抗體-藥物結合物及atm抑制劑之組合 |
| BR112023002078A2 (pt) | 2020-09-18 | 2023-03-28 | Merck Patent Gmbh | Preparação farmacêutica |
| KR20230026478A (ko) | 2020-09-21 | 2023-02-24 | 웨이 중 | 혈액-뇌 장벽 투과능을 가진 치환된 1-(3,3-디플루오로피페리딘-4-일)-이미다조[4,5-c] 퀴놀린-2-온 화합물 |
| EP3992191A1 (en) | 2020-11-03 | 2022-05-04 | Deutsches Krebsforschungszentrum | Imidazo[4,5-c]quinoline compounds and their use as atm kinase inhibitors |
| CN115232122A (zh) * | 2021-04-23 | 2022-10-25 | 石药集团中奇制药技术（石家庄）有限公司 | 炔类化合物及其制备和应用 |
| CN115716829A (zh) * | 2022-11-13 | 2023-02-28 | 药康众拓(江苏)医药科技有限公司 | 一种喹啉并咪唑酮联氘代吡唑类化合物及其应用 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0211649D0 (en) | 2002-05-21 | 2002-07-03 | Novartis Ag | Organic compounds |
| DK1879893T3 (da) | 2005-03-21 | 2010-09-13 | Ferrer Int | Fremgangsmåde til fremstilling af 1-substituerede 1H-imidazo[4,5-c]quinolin-4-aminforbindelser og mellemprodukter dertil |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| CN101616672A (zh) | 2007-02-20 | 2009-12-30 | 诺瓦提斯公司 | 作为脂质激酶和mTOR双重抑制剂的咪唑并喹啉类 |
| BRPI0909082A2 (pt) | 2008-03-26 | 2019-02-26 | Novartis Ag | imidazoquinolinas e derivados de pirimidina como moduladores potentes de processos angiogênicos acionados por vegf |
| PE20140407A1 (es) * | 2008-06-10 | 2014-04-25 | Abbott Lab | Nuevos compuestos triciclicos |
| MX340304B (es) | 2008-10-01 | 2016-07-05 | Novartis Ag * | Antagonismo de smoothened para el tratamiento de los trastornos relacionados con la senda de hedgehog. |
| EP2438064A1 (en) * | 2009-06-04 | 2012-04-11 | Novartis AG | 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES |
| EP2438063A1 (en) | 2009-06-04 | 2012-04-11 | Novartis AG | 1h-imidazo[4,5-c]quinolinone compounds, useful for the treatment of proliferative diseases |
| GB0919423D0 (en) * | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| BR112012022868A2 (pt) * | 2010-03-16 | 2018-06-05 | Merck Patent Gmbh | morfolinilquinazolinas |
| PE20130376A1 (es) * | 2010-06-28 | 2013-03-30 | Merck Patent Gmbh | [1,8]naftiridinas sustituidas por 2,4-diarilo como inhibidores de quinasas para uso contra el cancer |
| CN102372711B (zh) | 2010-08-18 | 2014-09-17 | 山东轩竹医药科技有限公司 | 咪唑并喹啉类PI3K和mTOR双重抑制剂 |
| DE102010035744A1 (de) | 2010-08-28 | 2012-03-01 | Merck Patent Gmbh | Imidazolonylchinoline |
| CN102399218A (zh) * | 2010-09-16 | 2012-04-04 | 和记黄埔医药（上海）有限公司 | 一类并合三杂环及其作为pi3k抑制剂的用途 |
| PE20140792A1 (es) | 2010-12-03 | 2014-07-09 | Novartis Ag | Composiciones farmaceuticas |
| CN103012398B (zh) | 2011-09-19 | 2015-10-14 | 上海恒瑞医药有限公司 | 咪唑并喹啉类衍生物及其可药用盐、其制备方法及其在医药上的应用 |
| US9879003B2 (en) | 2012-04-11 | 2018-01-30 | Dana-Farber Cancer Institute, Inc. | Host targeted inhibitors of dengue virus and other viruses |
| CN104349771A (zh) | 2012-06-06 | 2015-02-11 | 诺华股份有限公司 | 用于***疾病的17α-羟化酶(C17,20-裂解酶)抑制剂和特定PI-3K抑制剂的组合 |
| NO2714752T3 (hr) * | 2014-05-08 | 2018-04-21 | ||
| ES2880626T3 (es) * | 2015-04-02 | 2021-11-25 | Merck Patent Gmbh | Imidazolonilquinolinas |
-
2016
- 2016-03-31 ES ES19172903T patent/ES2880626T3/es active Active
- 2016-03-31 WO PCT/EP2016/000542 patent/WO2016155884A1/de active Application Filing
- 2016-03-31 CN CN201680031887.8A patent/CN107889488B/zh active Active
- 2016-03-31 CA CA2981365A patent/CA2981365A1/en active Pending
- 2016-03-31 KR KR1020177031770A patent/KR102652052B1/ko active IP Right Grant
- 2016-03-31 MX MX2020011558A patent/MX2020011558A/es unknown
- 2016-03-31 EP EP16717560.3A patent/EP3277681B1/de active Active
- 2016-03-31 CN CN202010644109.4A patent/CN111747952A/zh active Pending
- 2016-03-31 LT LTEP19172903.7T patent/LT3560924T/lt unknown
- 2016-03-31 TR TR2019/11244T patent/TR201911244T4/tr unknown
- 2016-03-31 PT PT191729037T patent/PT3560924T/pt unknown
- 2016-03-31 ES ES21165573T patent/ES2946507T3/es active Active
- 2016-03-31 SG SG10202002181UA patent/SG10202002181UA/en unknown
- 2016-03-31 HU HUE16717560A patent/HUE045477T2/hu unknown
- 2016-03-31 BR BR122019005502-5A patent/BR122019005502B1/pt active IP Right Grant
- 2016-03-31 DK DK19172903.7T patent/DK3560924T3/da active
- 2016-03-31 RS RS20190993A patent/RS59139B1/sr unknown
- 2016-03-31 AU AU2016239270A patent/AU2016239270B2/en active Active
- 2016-03-31 EP EP21165573.3A patent/EP3868761B1/de active Active
- 2016-03-31 LT LTEP16717560.3T patent/LT3277681T/lt unknown
- 2016-03-31 PT PT16717560T patent/PT3277681T/pt unknown
- 2016-03-31 HU HUE19172903A patent/HUE054745T2/hu unknown
- 2016-03-31 CN CN202010644289.6A patent/CN111689963A/zh active Pending
- 2016-03-31 PL PL16717560T patent/PL3277681T3/pl unknown
- 2016-03-31 SI SI201630345T patent/SI3277681T1/sl unknown
- 2016-03-31 KR KR1020247009513A patent/KR20240044525A/ko active Search and Examination
- 2016-03-31 PL PL19172903T patent/PL3560924T3/pl unknown
- 2016-03-31 EP EP19172903.7A patent/EP3560924B1/de active Active
- 2016-03-31 MX MX2017012613A patent/MX2017012613A/es active IP Right Grant
- 2016-03-31 ES ES16717560T patent/ES2741853T3/es active Active
- 2016-03-31 DK DK16717560.3T patent/DK3277681T3/da active
- 2016-03-31 RU RU2017138100A patent/RU2743343C2/ru active
- 2016-03-31 US US15/563,680 patent/US10457677B2/en active Active
- 2016-03-31 SI SI201631240T patent/SI3560924T1/sl unknown
- 2016-03-31 JP JP2017551589A patent/JP6791873B2/ja active Active
- 2016-03-31 RS RS20210817A patent/RS62082B1/sr unknown
- 2016-03-31 SG SG11201708065QA patent/SG11201708065QA/en unknown
-
2017
- 2017-09-26 IL IL254714A patent/IL254714B/en active IP Right Grant
- 2017-11-01 ZA ZA2017/07423A patent/ZA201707423B/en unknown
-
2019
- 2019-03-14 US US16/353,559 patent/US10745399B2/en active Active
- 2019-08-01 HR HRP20191396 patent/HRP20191396T1/hr unknown
- 2019-12-17 IL IL271494A patent/IL271494B/en active IP Right Grant
-
2020
- 2020-06-24 US US16/910,438 patent/US10975075B2/en active Active
- 2020-06-25 AU AU2020204241A patent/AU2020204241B2/en active Active
- 2020-11-05 JP JP2020185129A patent/JP7111790B2/ja active Active
-
2021
- 2021-03-17 US US17/204,619 patent/US11608338B2/en active Active
- 2021-04-22 IL IL282584A patent/IL282584B/en unknown
- 2021-06-23 HR HRP20210981TT patent/HRP20210981T1/hr unknown
-
2022
- 2022-10-21 AU AU2022256215A patent/AU2022256215A1/en active Pending
-
2023
- 2023-03-01 US US18/116,094 patent/US20230203034A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20210981T1 (hr) | Imidazolonil kinolini i njihova uporaba kao inhibitori atm kinaze | |
| HRP20180382T1 (hr) | Inhibitori protein kinaze | |
| Ku et al. | Caffeine inhibits cell proliferation and regulates PKA/GSK3β pathways in U87MG human glioma cells | |
| JP2014070075A5 (hr) | ||
| CU24355B1 (es) | Derivados de 2((( oxadiazol/triazol/tetrazol/isoxazol) metil) fenil)-1-(heterociclil)-ona como inhibidores activos de autotaxina | |
| HRP20160421T1 (hr) | Derivat azola | |
| JP2016535772A5 (hr) | ||
| HRP20161396T1 (hr) | Derivati 2-(fenil ili pirid-3-il)aminopirimidina kao modulatori lrrk2-kinaze za liječenje parkinsonove bolesti | |
| GT201700094A (es) | Derivados de feniltriazol sustituido con hidroxialquilo y sus usos | |
| JP2018510191A5 (hr) | ||
| JP2017528504A5 (hr) | ||
| TN2012000347A1 (en) | 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride polymorphs and solvates | |
| ZA201803747B (en) | 4-((6-2-(2,4-difluorophenyl)-1,1-difluoro-2-hydroxy-3-(1h-1,2,4-triazol-1-yl)propyl)pyridin-3-yl)oxy)benzonitrile and processes of preparation | |
| RU2014147381A (ru) | Производные пиразоламинопиримидина в качестве модуляторов обогащенной лейциновыми повторами киназы 2 | |
| JP2015531366A5 (hr) | ||
| PE20081379A1 (es) | Composiciones farmaceuticas que comprende nilotinib | |
| US20160264564A1 (en) | Pyrazol-3-ones That Activate Pro-apoptotic BAX | |
| Wang et al. | Design, synthesis and biological evaluation of bromophenol-thiazolylhydrazone hybrids inhibiting the interaction of translation initiation factors eIF4E/eIF4G as multifunctional agents for cancer treatment | |
| Abd-Rabou et al. | Synthesis, molecular docking, and evaluation of novel bivalent pyrazolinyl-1, 2, 3-triazoles as potential VEGFR TK inhibitors and anti-cancer agents | |
| Zhang et al. | Biological activities of novel pyrazolyl hydroxamic acid derivatives against human lung cancer cell line A549 | |
| JP2014208663A5 (hr) | ||
| AR108265A1 (es) | Derivados de feniltriazol sustituidos con amida y usos de estos | |
| JP2016520635A5 (hr) | ||
| JP2015524825A5 (hr) | ||
| CO2018011948A2 (es) | Procedimiento para la preparación de derivados de 1-fenilo-1,2,4- triazol sustituidos por 5-hidroxialquilo |